HRP20180524T1 - Derivati tipa azaindazola ili diazaindazola kao lijek - Google Patents

Derivati tipa azaindazola ili diazaindazola kao lijek Download PDF

Info

Publication number
HRP20180524T1
HRP20180524T1 HRP20180524TT HRP20180524T HRP20180524T1 HR P20180524 T1 HRP20180524 T1 HR P20180524T1 HR P20180524T T HRP20180524T T HR P20180524TT HR P20180524 T HRP20180524 T HR P20180524T HR P20180524 T1 HRP20180524 T1 HR P20180524T1
Authority
HR
Croatia
Prior art keywords
group
image
compound according
compound
groups
Prior art date
Application number
HRP20180524TT
Other languages
English (en)
Croatian (hr)
Inventor
El Bachir Kaloun
Karim Bedjeguelal
Rémi RABOT
Anna Kruczynski
Philippe Schmitt
Michel Perez
Nicolas Rahier
Original Assignee
Pierre Fabre Médicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Médicament filed Critical Pierre Fabre Médicament
Publication of HRP20180524T1 publication Critical patent/HRP20180524T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20180524TT 2011-01-27 2012-01-27 Derivati tipa azaindazola ili diazaindazola kao lijek HRP20180524T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1150651A FR2970967B1 (fr) 2011-01-27 2011-01-27 Derives de type azaindazole ou diazaindazole comme medicament
EP12701884.4A EP2668184B1 (en) 2011-01-27 2012-01-27 Derivatives of azaindazole or diazaindazole type as medicament
PCT/EP2012/051283 WO2012101239A1 (en) 2011-01-27 2012-01-27 Derivatives of azaindazole or diazaindazole type as medicament

Publications (1)

Publication Number Publication Date
HRP20180524T1 true HRP20180524T1 (hr) 2018-05-04

Family

ID=44318089

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180524TT HRP20180524T1 (hr) 2011-01-27 2012-01-27 Derivati tipa azaindazola ili diazaindazola kao lijek

Country Status (30)

Country Link
US (2) US20130172360A1 (OSRAM)
EP (1) EP2668184B1 (OSRAM)
JP (1) JP5931926B2 (OSRAM)
KR (2) KR20180122028A (OSRAM)
CN (1) CN103339129B (OSRAM)
AR (1) AR084935A1 (OSRAM)
AU (1) AU2012210467B2 (OSRAM)
BR (1) BR112013018852B1 (OSRAM)
CA (1) CA2823824C (OSRAM)
CY (1) CY1120088T1 (OSRAM)
DK (1) DK2668184T3 (OSRAM)
ES (1) ES2661695T3 (OSRAM)
FR (1) FR2970967B1 (OSRAM)
HR (1) HRP20180524T1 (OSRAM)
HU (1) HUE037153T2 (OSRAM)
IL (2) IL227496B (OSRAM)
LT (1) LT2668184T (OSRAM)
MA (1) MA34903B1 (OSRAM)
MX (1) MX356411B (OSRAM)
MY (1) MY180666A (OSRAM)
PL (1) PL2668184T3 (OSRAM)
PT (1) PT2668184T (OSRAM)
RS (1) RS57101B1 (OSRAM)
RU (1) RU2600976C2 (OSRAM)
SI (1) SI2668184T1 (OSRAM)
TN (1) TN2013000293A1 (OSRAM)
TR (1) TR201802944T4 (OSRAM)
TW (1) TWI546303B (OSRAM)
UA (1) UA109698C2 (OSRAM)
WO (1) WO2012101239A1 (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
BR112014020773A2 (pt) 2012-02-22 2020-10-27 Sanford-Burnham Medical Research Institute compostos de sulfonamida e seus usos como inibidores tnap
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
EP2689779A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3233840B1 (en) 2014-12-16 2018-11-21 Eudendron S.r.l. Heterocyclic derivatives modulating activity of certain protein kinases
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US10211205B2 (en) * 2016-04-27 2019-02-19 International Business Machines Corporation Field effect transistor structure for reducing contact resistance
CN108570052A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元杂环并吡嗪化合物、制备方法、中间体、组合和应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN112313232B (zh) * 2018-05-02 2024-03-08 Jw中外制药公司 新型杂环衍生物
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Fgfr阻害剤としての三環式複素環
CN115151539A (zh) 2019-12-04 2022-10-04 因赛特公司 Fgfr抑制剂的衍生物
WO2021138419A1 (en) * 2019-12-31 2021-07-08 Ifm Due, Inc, Compounds and compositions for treating conditions associated with sting activity
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN115916771B (zh) * 2020-04-02 2025-04-01 浙江华海药业股份有限公司 多靶点的抗肿瘤化合物及其制备方法和应用
GB2617477A (en) * 2020-11-20 2023-10-11 2692372 Ontario Inc Benzenesulfonamide derivatives and uses thereof
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2283961A1 (en) * 1997-03-19 1998-09-24 Basf Aktiengesellschaft Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
EP1215208B1 (en) 1997-10-27 2006-07-12 Agouron Pharmaceuticals, Inc. 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
HUP0301183A3 (en) 2000-06-22 2006-02-28 Pfizer Process for the preparation of pyrazolopyrimidinones
WO2003068773A1 (en) * 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
CN101243090A (zh) * 2005-08-25 2008-08-13 霍夫曼-拉罗奇有限公司 p38 MAP激酶抑制剂及使用它的方法
CA2657287A1 (en) 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
EA017852B1 (ru) 2006-12-20 2013-03-29 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные замещенных индазолов, активные в качестве ингибиторов киназ
HUE030929T2 (en) 2007-07-20 2017-06-28 Nerviano Medical Sciences Srl Substituted indazole derivatives active as kinase inhibitors
WO2010069966A1 (en) 2008-12-18 2010-06-24 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament

Also Published As

Publication number Publication date
AU2012210467A1 (en) 2013-09-12
RU2600976C2 (ru) 2016-10-27
TN2013000293A1 (en) 2015-01-20
CA2823824A1 (en) 2012-08-02
AR084935A1 (es) 2013-07-10
FR2970967A1 (fr) 2012-08-03
RS57101B1 (sr) 2018-06-29
TWI546303B (zh) 2016-08-21
BR112013018852B1 (pt) 2021-12-21
US8883821B2 (en) 2014-11-11
CN103339129B (zh) 2015-07-29
MY180666A (en) 2020-12-04
IL257748B (en) 2020-06-30
MA34903B1 (fr) 2014-02-01
US20130085144A1 (en) 2013-04-04
IL227496A0 (en) 2013-09-30
DK2668184T3 (en) 2018-03-12
US20130172360A1 (en) 2013-07-04
UA109698C2 (xx) 2015-09-25
EP2668184A1 (en) 2013-12-04
PL2668184T3 (pl) 2018-06-29
HUE037153T2 (hu) 2018-08-28
LT2668184T (lt) 2018-04-10
EP2668184B1 (en) 2018-01-10
TR201802944T4 (tr) 2018-03-21
FR2970967B1 (fr) 2013-02-15
CY1120088T1 (el) 2018-12-12
KR20180122028A (ko) 2018-11-09
JP5931926B2 (ja) 2016-06-08
TW201247664A (en) 2012-12-01
ES2661695T3 (es) 2018-04-03
RU2013138624A (ru) 2015-03-10
IL257748A (en) 2018-04-30
MX356411B (es) 2018-05-24
MX2013008673A (es) 2013-12-02
CN103339129A (zh) 2013-10-02
IL227496B (en) 2019-02-28
WO2012101239A1 (en) 2012-08-02
SI2668184T1 (en) 2018-06-29
KR20140014147A (ko) 2014-02-05
BR112013018852A2 (pt) 2017-08-15
KR101923751B1 (ko) 2018-11-29
AU2012210467B2 (en) 2016-07-07
PT2668184T (pt) 2018-03-13
NZ614432A (en) 2015-03-27
CA2823824C (en) 2018-12-11
HK1186737A1 (en) 2014-03-21
JP2014503574A (ja) 2014-02-13

Similar Documents

Publication Publication Date Title
HRP20180524T1 (hr) Derivati tipa azaindazola ili diazaindazola kao lijek
HRP20170104T1 (hr) Derivati tipa azaindazola ili diazaindazola za liječenje boli
RU2403258C2 (ru) Тиазолилдигидроиндазолы
JP2017511360A5 (OSRAM)
RU2397168C2 (ru) Производные тиофена в качестве ингибиторов снк 1
RU2014141579A (ru) Гетероциклические соединения в качестве ингибиторов бета-лактамаз
JP2014503574A5 (OSRAM)
JP2013523614A5 (OSRAM)
ES2543645T3 (es) Ligandos sigma para la prevención o el tratamiento de dolor inducido por quimioterapia
RU2013148922A (ru) Три- и тетрациклические пиразоло[3,4-в]пиридины в качестве антинеопластического средства
JP2013512903A5 (OSRAM)
DE69733825D1 (de) Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
AR083200A1 (es) Compuestos de n-heteroarilo
RU2006132071A (ru) Производные антраниловой кислоты, способы их получения и применение
BR0113057A (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para produzir um efeito antiangiogênico e/ou efeito de redução da permeabilidade vascular em um animal de sangue quente em necessidade de tal tratamento
RU2011119450A (ru) Содержащее конденсированную кольцевую структуру производное и его применение в медицине
CA3155875A1 (en) BIARYL COMPOUND SUBSTITUTED BY SULFO OR CORRESPONDING SALT, METHOD FOR PREPARATION AND USE
EA202190036A1 (ru) Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение
ES2388253B1 (es) Ligandos sigma para la prevención o el tratamiento de dolor inducido por quimioterapia
MX2023009094A (es) Derivados de imidazo[4,5-d]piridazina, su preparacion y su aplicacion terapeutica.
HRP20241522T1 (hr) Derivati 10-(di(fenil)metil)-4-hidroksi-8,9,9a,10-tetrahidro-7h-pirolo[1',2':4,5]pirazino[1,2-b]piridazin-3,5-diona i odgovarajući spojevi kao inhibitori replikacije ortomiksovirusa za liječenje gripe
AR050947A1 (es) Derivados de 3,4-dihidro-3-metil-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazina-8-carboxilato
RU2019123982A (ru) Комбинация mcl-1 ингибитора и таксанового соединения, их применения и фармацевтические композиции
RU2006117639A (ru) Комбинированное лечение ожирения с привлечением производных 4, 5-дигидро-1н-пиразола, обладающих антагонистической активностью по отношению к св1, и ингибиторов липазы
JPWO2021100029A5 (OSRAM)